GW Pharmaceuticals (GW), and U.S. subsidiary Greenwich Biosciences, is a global biopharmaceutical company that has established a world-leading position in cannabinoid science and medicines. Founded over two decades ago in response to significant unmet patient need, patients remain our key focus and improving their quality of life, our motivation.

GW’s pioneering work has led to the regulatory approval of world first, potentially life changing, cannabis-based medicines in 42 countries around the world. Our continued dedication has resulted in the treatment of thousands of patients with our medicines, including more than 8,000 as part of our clinical trials programmes.

Much of what is known about cannabis and its medical uses was discovered by us – we have led the way in understanding cannabinoid science and how, if harnessed correctly it has the potential to transform the lives of patients and their families. In the process, we have collaborated with more than 1,000 institutions, invested £700 million in R&D and £600 million in infrastructure and facilities, and collected upwards of 135,000 patient-years of human safety data from post-marketing sources.

Looking to the future, GW is committed to leveraging our experience, expertise and extensive body of research in cannabinoid science to treat other diseases where significant unmet need exists.

Our global employee population recently exceeded 1,000 and we continue to grow. In the UK we have close to 700 employees from a diverse range of backgrounds and disciplines based in our Cambridge, Kent, London and Andover sites, along with employees working in the field. Our broader European footprint now includes employees across the EU5, the Netherlands and Switzerland, with further planned expansion. We also have a strong presence in the U.S. with more than 300 employees based in Carlsbad, California, and in the field throughout the country.

In 2018 our achievements were recognized by TIME magazine which named GW as one of the ‘Top 50 Genius companies that are inventing the future’, alongside a Scrip Award for Clinical Advance of the Year.

We are proud of our inclusive, values-based culture which celebrates diversity and creates a sense of purpose, belonging and engagement. Our aim is that every person at GW is valued for who they are, can develop themselves and their careers at the company, and feel a direct connection between the work they do and the patients we serve.

Please go to www.gwpharm.com for additional information.